Disease Domain | Count |
---|---|
Neoplasms | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
GPR120 x PPARγ | 1 |
Target |
Mechanism GPR120 agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Taste 2 receptors modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
KDT-501 ( GPR120 x PPARγ ) | Polycystic Ovary Syndrome More | Preclinical |
KDT-C0D ( Taste 2 receptors ) | Obesity More | Pending |
KDT-A0B ( Taste 2 receptors ) | Respiration Disorders More | Pending |
KDT-600 | Obesity More | Pending |
KDT-500 ( GPR120 x PPARγ ) | Diabetes Mellitus, Type 2 More | Pending |